Want to see TSE:AVCR full AI Analyst Report?
Top Page
Avricore Health
(AVCR)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.06
▼(-26.25% Downside)
Action:Reiterated
Date:09/11/26
The score is held down primarily by deteriorating financial performance (very low TTM revenue, negative gross profit, widening losses, and negative operating/free cash flow), only partly offset by a low-debt balance sheet. Technical indicators are neutral-to-mildly positive, but valuation is hard to support with a negative P/E and no dividend data.
Positive Factors
Zero Debt
A debt-free balance sheet gives Avricore greater financial flexibility than a leveraged peer during a difficult operating period. It avoids mandatory interest and refinancing obligations, allowing management to direct available resources toward HealthTab adoption and operational recovery.
Negative Factors
Severe Revenue Deterioration
The sharp decline from the stronger 2023–2024 revenue base weakens evidence of sustained commercial traction. Very low trailing revenue can reduce operating scale, make fixed costs harder to absorb, and increase dependence on a successful rebound in pharmacy sites and testing volumes.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero Debt
A debt-free balance sheet gives Avricore greater financial flexibility than a leveraged peer during a difficult operating period. It avoids mandatory interest and refinancing obligations, allowing management to direct available resources toward HealthTab adoption and operational recovery.
Read all positive factors
Avricore Health (AVCR) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$9.22M
Dividend YieldN/A
Average Volume (3M)33.52K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue Growth-93.73%
EPS Growth-25.53%
CountryCA
Employees26
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.02
Shares Outstanding126,369,670
10 Day Avg. Volume38,868
30 Day Avg. Volume33,515
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)13.00
Price to Sales (P/S)9.49
P/FCF Ratio-5.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Avricore Health Business Overview & Revenue Model
Company Description
Avricore Health Inc. operates within Canada, specializing in health data management and point-of-care technological solutions. Their primary offering is HealthTab, a precise, laboratory-quality diagnostic testing system designed for use in pharmac...
How the Company Makes Money
Avricore Health primarily makes money by commercializing its pharmacy-based POCT ecosystem centered on the HealthTab platform. Revenue is generated from (1) fees tied to the deployment and ongoing use of HealthTab by pharmacies (e.g., platform/sof...
Avricore Health Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 193.04K | 533.88K | 4.79M | 3.49M | 1.77M | 122.81K |
| Gross Profit | -70.94K | 236.33K | 1.88M | 1.20M | 456.79K | 30.52K |
| EBITDA | -1.23M | -1.23M | -208.44K | -275.14K | -629.76K | -1.64M |
| Net Income | -1.80M | -1.86M | -668.98K | -701.22K | -818.23K | -1.71M |
Balance Sheet | ||||||
| Total Assets | 1.24M | 563.13K | 2.30M | 2.54M | 2.57M | 2.28M |
| Cash, Cash Equivalents and Short-Term Investments | 922.55K | 237.92K | 1.14M | 286.57K | 630.53K | 2.01M |
| Total Debt | 0.00 | 0.00 | 0.00 | 40.00K | 40.00K | 40.00K |
| Total Liabilities | 129.17K | 173.56K | 330.82K | 529.22K | 604.89K | 84.48K |
| Stockholders Equity | 1.11M | 389.56K | 1.97M | 2.01M | 1.96M | 2.20M |
Cash Flow | ||||||
| Free Cash Flow | -1.13M | -904.29K | 799.27K | -386.46K | -1.64M | -1.37M |
| Operating Cash Flow | -1.10M | -789.93K | 1.00M | 660.40K | -437.83K | -1.23M |
| Investing Cash Flow | -29.20K | -114.36K | -205.35K | -1.05M | -1.21M | -140.36K |
| Financing Cash Flow | 1.19M | 0.00 | 56.60K | 42.50K | 253.88K | 3.08M |
Avricore Health Technical Analysis
Positive
0.08
Price Trends
0.06
Positive
0.06
Positive
0.06
Positive
Market Momentum
<0.01
Negative
55.73
Neutral
36.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AVCR, the sentiment is Positive. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.06, and above the 200-day MA of 0.06, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.73 is Neutral, neither overbought nor oversold. The STOCH value of 36.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AVCR.
Avricore Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$4.52M | -1.93 | 902.36% | ― | ― | 26.96% | |
47 Neutral | C$9.22M | -3.41 | -241.33% | ― | -93.73% | -25.53% | |
42 Neutral | C$52.18M | -35.56 | -250.77% | ― | -82.05% | 23.73% | |
41 Neutral | C$4.21M | -1.45 | 184.91% | ― | ― | 43.30% |
* Healthcare Sector Average
TSE:AVCR
Avricore Health
0.06
>-0.01
-7.69%
TSE:BUX
BioMark Diagnostics
0.48
0.11
31.51%
TSE:TELO
Telo Genomics Corp
0.05
-0.04
-43.75%
TSE:SZLS.H
StageZero Life Sciences Ltd
0.04
0.00
0.00%
TSE:NARA
PanGenomic Health, Inc. Class A
0.30
-1.95
-86.67%
Avricore Health Corporate Events
Business Operations and StrategyProduct-Related Announcements
Avricore’s HealthTab Wins National NHS Role in England’s Pharmacy Cholesterol Drive
Positive
Sep 1, 2026
NHS England has approved a national rollout of the Barts Health pharmacy cholesterol testing initiative using Avricore’s HealthTab platform. Around 100 pharmacies across England will begin offering seven-minute cholesterol checks this fall, ...
Business Operations and StrategyExecutive/Board Changes
Avricore Grants Stock Options as HealthTab PoCT Platform Expands and Tightens Quality Controls
Positive
Aug 28, 2026
Avricore Health has granted stock options exercisable for 3,300,000 common shares at an exercise price of CAD $0.06 to its directors, officers, employees, and consultants under its stock option plan, with options vesting quarterly and expiring fiv...
Business Operations and StrategyProduct-Related Announcements
Avricore’s HealthTab Strikes Landmark UK Point-of-Care Testing Deal with Abbott
Positive
Aug 20, 2026
Avricore Health’s subsidiary HealthTab has signed a multi-year collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products through the HealthTab platform across the U.K. pharmacy network. The de...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.